by The US mRNA therapeutics market size accounted for US$ 11.07 billion in 2023 and is projected to reach around USD 38.21 billion by 2033, growing at a CAGR of 13.21% from 2024 to 2033.
Key Points
- By type, the prophylactic vaccines segment held the largest share of the market in 2023.
- By application, the infectious disease segment led the market in 2023. The segment is observed to sustain the growth rate during the forecast period.
- By end-use, the hospital and clinics segment held the largest share of the market in 2023. The segment is expected to sustain its position throughout the forecast period.
Report Summary
The global US mRNA therapeutics market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the US mRNA therapeutics market across the globe.
A comprehensive estimate on the US mRNA therapeutics market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of US mRNA therapeutics during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3862
US mRNA Therapeutics Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 13.21% |
| U.S. Market Size in 2023 | USD 11.07 Billion |
| U.S. Market Size by 2033 | USD 38.21 Billion |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Type, By Application, and By End User |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized US mRNA therapeutics market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: Telecom Electronic Manufacturing Services Market Size, Growth, Report By 2033
Market Players
The report includes the profiles of key US mRNA therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Recent Developments:
- In July 2023, MIT scientists are leading a three-year research study financed by the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research that intends to build the first fully integrated, continuous mRNA production platform in history. The project is valued at $82 million. In addition to accelerating the development and production of mRNA technologies—which businesses are investing in at previously unheard-of levels in the hopes of creating novel vaccines and treatments for cancer, metabolic disorders, genetic diseases, and other conditions—the resulting pilot-scale system is meant to strengthen society’s capacity to respond to pandemics in the future.
US mRNA Therapeutics Market Companies
- GSK plc.
- BioNTech SE
- CureVac N.V.
- Sangamo Therapeutics, Inc.
- Translate Bio, Inc.
- Moderna, Inc.
- Argos Therapeutics Inc.
- Arcturus Therapeutics
- AstraZeneca plc.
- Pfizer Inc.
- CRISPR Therapeutics AG
Segments Covered in the Report
By Type
- Therapeutic Vaccines
- Prophylactic Vaccines
- Therapeutic Drugs
By Application
- Respiratory Diseases
- Oncology
- Rare Genetic Diseases
- Infectious Diseases
- Others
By End-use
- Research Organizations
- Hospitals & Clinics
- Others
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on US mRNA Therapeutics Market
5.1. COVID-19 Landscape: US mRNA Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global US mRNA Therapeutics Market, By Type
8.1. US mRNA Therapeutics Market, by Type, 2023-2032
8.1.1 Therapeutic Vaccines
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Prophylactic Vaccines
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Therapeutic Drugs
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global US mRNA Therapeutics Market, By Application
9.1. US mRNA Therapeutics Market, by Application, 2023-2032
9.1.1. Respiratory Diseases
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Oncology
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Rare Genetic Diseases
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Infectious Diseases
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global US mRNA Therapeutics Market, By End-use
10.1. US mRNA Therapeutics Market, by End-use, 2023-2032
10.1.1. Research Organizations
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Hospitals & Clinics
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global US mRNA Therapeutics Market, Trend Forecast
11.1. US
11.1.1. Market Revenue and Forecast, by Type (2020-2032)
11.1.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.3. Market Revenue and Forecast, by End-use (2020-2032)
US mRNA Therapeutics Market
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on US mRNA Therapeutics Market
5.1. COVID-19 Landscape: US mRNA Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global US mRNA Therapeutics Market, By Type
8.1. US mRNA Therapeutics Market, by Type, 2024-2033
8.1.1 Therapeutic Vaccines
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Prophylactic Vaccines
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Therapeutic Drugs
8.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global US mRNA Therapeutics Market, By Application
9.1. US mRNA Therapeutics Market, by Application, 2024-2033
9.1.1. Respiratory Diseases
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Oncology
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Rare Genetic Diseases
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Infectious Diseases
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global US mRNA Therapeutics Market, By End-use
10.1. US mRNA Therapeutics Market, by End-use, 2024-2033
10.1.1. Research Organizations
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Hospitals & Clinics
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global US mRNA Therapeutics Market, Trend Forecast
11.1. US
11.1.1. Market Revenue and Forecast, by Type (2021-2033)
11.1.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.3. Market Revenue and Forecast, by End-use (2021-2033)
Chapter 12. Company Profiles
12.1. GSK plc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. BioNTech SE
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. CureVac N.V.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Sangamo Therapeutics, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Translate Bio, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Moderna, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Argos Therapeutics Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Arcturus Therapeutics
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AstraZeneca plc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Pfizer Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
